B2PAC, SCD-iBIO Form Alliance to Advance Commercialization of Industrial Biotechnology

0

Source: Acta Group

The Biobased Products Advocacy Consortium (B2PAC), an affiliate of Bergeson & Campbell, P.C. (B&C), and the Society for the Commercial Development of Industrial Biotechnology (SCD-iBIO), an affiliate of the Society of Chemical Manufacturers & Affiliates (SOCMA), announced today the formation of a new alliance to advance the commercialization of industrial biotechnology and biobased products. According to a recently released report from Lux Research, industrial biotechnology and biobased product development is experiencing a robust year in growth of 30%. Through a memorandum of understanding, B2PAC and SCD-iBIO have recognized the complementary nature of their missions and the benefit to the biobased chemical and industrial biotechnology communities of working cooperatively where appropriate.

'Our joint membership is enjoying unprecedented success in commercializing their products,' noted Lynn L. Bergeson, Managing Partner of B&C. 'Our regulatory challenges are many, but so are our opportunities for advocacy and legislative relief. Our legal and advocacy firepower coupled with SCD-iBIO's depth and technical skills has made our alliance a formidable force -- businesses in this space are urged to join and benefit from our unique strengths in areas directly impacting commercialization potential.'

Larry Drumm, Co-executive Director of SCD-iBIO, added 'SCD-iBIO was formed to accelerate the penetration of industrial biotechnology by educating the industry on up-to-date information and best practices. We are proud of our developing relationship with B2PAC, which provides the expertise to accelerate the commercialization of biobased and green chemistry into the chemical, plastics, and fuels markets. Together, we will offer the industry this knowledge via webinars and workshops.'

B&C, through its affiliate B&C Consortia Management, L.L.C., launched B2PAC in 2012 to help members bring their innovative biobased chemical products to market. Members receive strategic insight into regulatory and legislative topics that are critical to their businesses, and collectively provide an informed advocacy voice for policy change. B2PAC's focus issues include building regulatory awareness of biobased chemicals and seeking regulatory relief in key compliance areas; navigating Toxic Substances Control Act requirements; and engaging in the legislative process to advocate for the biobased products industry.

SCD-iBIO was established by SOCMA to help members gather the in-depth, multi-faceted resources needed to validate best practices for issues in the business, market, and technical areas facing industry now and those that will evolve in the future. Through member meetings that provide a forum to learn and participate in formulating best practices, working groups that focus on specific issues throughout the various stages of the commercialization process, and access to education and networking opportunities, SCD-iBIO helps members bridge the gap between science and commercial reality and integrate industrial biotechnology innovation with market demand.

Contact Heidi Brown Lewis at 301-706-9635 or hlewis@lawbc.com.

For more information, visit www.b2pac.org, www.scd-ibio.org, www.lawbc.com, or www.socma.com.

Customer comments

No comments were found for B2PAC, SCD-iBIO Form Alliance to Advance Commercialization of Industrial Biotechnology. Be the first to comment!